Effect of Intensive Statin Therapy on Clinical Outcomes Among Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary SyndromePCI-PROVE IT: A PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Substudy
C. Michael Gibson, MS, MD*,*,
Yuri B. Pride, MD*,
Claudia P. Hochberg, MD*,
Sarah Sloan, MA, MS ,
Marc S. Sabatine, MD, MPH,
Christopher P. Cannon, MD for the TIMI Study Group
* TIMI Study Group, Cardiovascular Divisions, Departments of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Primary and Secondary End Points
Kaplan-Meier estimates of the incidence of the primary end point (A) and the composite of death, myocardial infarction (MI), recurrent ischemia (RI), and unstable angina (UA) requiring rehospitalization (B) among patients who underwent percutaneous coronary intervention for the index event. CI = confidence interval.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 TVR Versus Non-TVR
Incidence of target vessel revascularization (TVR) and non-TVR among patients who underwent percutaneous coronary intervention for the index event stratified by treatment allocation. Multivariate odds ratio (OR) adjusted for on-treatment low-density lipoprotein cholesterol and C-reactive protein concentrations.
|
|
|
